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Clostridioides difficile infection (CDI) is an urgent public health problem in the 
United States (U.S.). Nearly half a million patients suffer from and 29,000 patients die 
from CDI annually in the U.S. Importantly, prior studies have noted a disproportionate 
incidence of CDI among cancer patients. This may be due to a number of factors, 
including the underlying disease, immunosuppression, healthcare exposures, or 
medication exposures. Despite these trends, few studies have assessed cancer as an 
independent risk factor for CDI. Furthermore, limited data exist to describe the effect 
cancer has on CDI health outcomes or the most appropriate treatment approaches for 
cancer patients who develop CDI. The objectives of this study were to: 1) define the risk 
of CDI among cancer patients compared to non-cancer patients, 2) compare CDI clinical 
outcomes of patients with and without cancer, and 3) compare the effectiveness of CDI 
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antibiotic therapy on CDI clinical outcomes among cancer patients. This was a 
retrospective cohort study of CDI and non-CDI patients in the U.S. Veterans Health 
Administration. Data were obtained from the Veterans Affairs Informatics and 
Computing Infrastructure. A series of multivariable logistic regression models were 
conducted to determine the impact of cancer on CDI risk and health outcomes, including 
demographics, comorbidities, and healthcare and medication exposures as covariates. In 
aim 1, cancer (overall) was an independent risk factor for CDI (OR 1.41; 95% CI 1.35-
1.47). Metastatic disease was the strongest cancer predictor of CDI (OR 4.68; 95% CDI 
4.02-5.45). In aim 2, cancer was associated with an increased risk for 30-day mortality 
following the CDI episode (OR 1.44; 95% CI 1.33-1.55). In aim 3, there was no 
statistically significant difference in 30-day mortality among CDI cancer patients who 
received metronidazole or oral vancomycin (OR 1.08; 95% CI 0.87-1.34). These data will 
be important for informing further local and public health initiatives for preventing CDI 
in high-risk groups, like cancer patients, and guiding treatment approaches. 
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AN OVERVIEW OF CLOSTRIDIOIDES DIFFICILE INFECTION 
 
MICROBIOLOGY AND PATHOGENESIS 
Clostridioides difficile is a Gram-positive, spore-forming, anaerobic bacterium. It 
is ubiquitous in the environment, with C. difficile spores found in soil, food, and 
healthcare facilities. It can also be part of the gastrointestinal microbiome of humans. 
Colonization rates vary by age and by healthcare exposures. The majority (up to 90%) of 
healthy newborns are colonized with C. difficile, while very few (<2%) healthy adults are 
colonized. In contrast, adults who are hospitalized or in long-term care facilities can have 
much higher colonization rates (up to 50%).1  
 
Table 1.1 Gut colonization rates of C. difficile by age and healthcare exposures1 
 
Population % colonized 
Healthy neonates & infants 18-90% 
Healthy adults 0-15% 
Elderly, long-term care residents 0-51% 
Hospitalized patients  
     General inpatients 4-29% 
     Elderly 1-15% 
     Cystic fibrosis 18-47% 
     Healthcare personnel 0-13% 
 
Transmission can occur between hosts via the fecal-oral route as the vegetative 
form of C. difficile or as spores.2 In healthy patients, the gut ecosystem contains trillions 
of bacterial cells that play a critical role in human health. The composition and diversity 
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of the gut microbiota interact with the human host to prevent infection, limit 
accumulation of toxins, aid in digestion and metabolism, and provide for energy and 
nutrient extraction.3 Disruption of the normal gut microbiota is the mechanism by which 
C. difficile infection (CDI) develops in those patients who are already colonized with C. 
difficile or those who acquire C. difficile spores during a time of gastrointestinal 
microbiome dysbiosis. An overview of CDI pathogenesis in outlined in Figure 1.1.  
 





Once colonization is established, development of disease occurs due to 
sporulation and toxin production. Spores can germinate and produce new vegetative cells 
when conditions become favorable. Substances present in the intestine, most notably bile 
acids, amino acids, and short chain fatty acids (SCFAs) play a role in the regulation of C. 
difficile in the gut. For example, bile acids can induce spore germination into actively 
replicating vegetative cells. The primary bile acid taurocholate promotes germination,5 
while the secondary bile acid deoxycholate acts as a competitive inhibitor of taurocholate 
and suppressant of vegetative growth.6 The production of secondary bile acids by 
commensal microbiota modulates susceptibility to CDI. Loss of secondary bile acids in 
the colon following antibiotic treatment is strongly associated with susceptibility to CDI, 
and recovery from recurrent CDI following fecal microbiota transplantation (FMT) is 
highly correlated with recovery of secondary bile acid levels.7  
Toxins A and B (TcdA and TcdB, respectively) are the two main C. difficile 
virulence factors. It is currently unknown whether cellular adhesion or biofilm production 
is involved in this process. After uptake into the cell, TcdA causes cytoskeletal alterations 
that lead to the disruption of tight junctions between epithelial cells and allow both toxins 
to cross the epithelial barrier. Various immunomodulatory mediators, such as IL-6 and 
IL-8 by intestinal epithelial cells, are activated in response to the toxins, and further 
inflammation occurs around the epithelial cells.2,8 It is the inflammatory response and 
damage to the gastrointestinal lining that prompt symptomatic infection.  
Certain strains of C. difficile are non-toxin-producing; thus, colonization does not 
lead to clinical disease. Furthermore, patients with adequate IgG immune response to 
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toxin production may also be asymptomatically colonized. It is patients who cannot 
mount an immune response to toxins who develop symptomatic CDI (Figure 1.2).  
 
Figure 1.2 Model for clinical response after C. difficile colonization 
 
Given that CDI is a bacterial infection, it is treated with antibiotic therapy as 
described later. This therapy can further disrupt the gastrointestinal microbiome, leading 
to inadequate recovery of microbial diversity and function. If CDI is not adequately 
treated or spores remain after antibiotic therapy, the process of germination, vegetative 
growth, and toxin production can begin again, leading to recurrent disease. It is estimated 





CLINICAL PRESENTATION AND DIAGNOSIS 
Diarrhea is the most common manifestation of CDI. In most patients, diarrhea is 
mild to moderate (3-10 loose, watery stools in 24 hours) and may be self-limiting 
following discontinuation of inciting antibiotic therapy. Leukocytosis, fever, 
hematochezia, nausea, anorexia, and cramping may also occur.2 In more severe forms of 
the infection, pseudomembranes, which are elevated yellow plaques, develop on the 
intestinal epithelium and may be seen upon endoscopy. 2 In the most severe cases, CDI 
may present as fulminant colitis. Patients may present with severe lower quadrant or 
abdominal pain, and diarrhea can be absent in the case of paralytic ileus. Toxic 
megacolon, which is an acute toxic colitis with dilatation of the colon, may also occur 
with severe systemic symptoms.2 
The diagnosis of CDI is based primarily on clinical presentation, but imaging 
studies may also aid in diagnosis.10 The 2017 Society for Healthcare Epidemiology and 
Infectious Diseases Society of America (SHEA/IDSA)10 Clinical Practice Guidelines for 
CDI recommend clinical suspicion of CDI if the patient has frequent, new-onset diarrhea 
(≥ 3 unformed stools per day). Fever (> 102°F), abdominal distention, and leukocytosis 
may also be present. CDI should also be suspected in those patients presenting with CDI 
risk factors as described later.  
The gold standard for CDI diagnosis is the stool test. Tests should assess for the 
presence of toxigenic C. difficile, which may necessitate a combination of different 







Table 1.2 An overview of available CDI stool tests11 
Test Detects Sensitivity Specificity 
Toxigenic culture C. diff cells or spores High Low 
Nucleic acid amplification test Toxin genes High Moderate 
Glutamate dehydrogenase C. diff antigen High Low 
Cytotoxicity assay Free toxins High High 
Toxin enzyme immunoassay Free toxins Low Moderate 
 
RISK FACTORS 
Antimicrobial therapy is considered the most important risk factor for CDI. This 
is due to the disruption of the normal gut microbiota, which can occur in as little as one 
dose for surgical prophylaxis.12 Longer duration of therapy and exposure to multiple 
agents increases the risk of CDI development.13 CDI risk is more common with 
antibiotics that extensively disrupt the gastrointestinal microbiota, such as clindamycin, 
carbapenems, and extended-spectrum penicillins and cephalosporins (Table 1.3).  
 
Table 1.3 Antibiotics commonly associated with CDI risk14 
 
Commonly associated Occasionally associated Rarely associated 
Clindamycin 
Carbapenems 
Cephalosporins (3rd/4th gen.) 
Fluoroquinolones 
Penicillins 








The risk of CDI can vary geographically, though, depending on the resistance 
profiles of strains compared to the respective antimicrobial agent employed.15 Resistance 
to antibiotics used to treat CDI has not posed a significant threat.8  
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Other non-antibiotic classes of medications have been associated with CDI as 
well. First, gastric acid suppressants increase gastrointestinal pH. The pH in the stomach 
and duodenum promotes changes in the gut microbiota, inhibiting the growth of some 
species like Bifidobacterium;16 thus, gastric acid suppressants can decrease microbial 
diversity and predispose patients to CDI. Secondly, proton pump inhibitors (PPIs) can 
target bacterial proton pumps, potentially interfering with microbial function in the gut.  
A recent meta-analysis of 42 studies (n=313,000) found that PPI use increased the risk 
for initial (OR 1.74, 95% CI 1.47 to 2.05; 39 studies) and recurrent (OR 2.51, 95% CI 
1.16 to 5.44; three studies) CDI compared to non-use.17 A second class of non-antibiotics 
that may increase the risk for CDI includes specific chemotherapeutic agents.18 A more 
thorough discussion of the association between cancer, chemotherapy, and CDI will be 
discussed in Chapter 2.  
Other CDI risk factors are primarily related to poor underlying immune response 
and healthcare exposures. Inadequate immune response as a function of older age, severe 
underlying disease, or immunosuppression can predispose to CDI due to insufficient IgG 
response to C. difficile toxins. Exposure to C. difficile spores through environmental 
exposures is another important risk factor. Specifically, hospitalization, inadequate 
isolation from other infected patients, and long-term care residence have been associated 






The 2017 SHEA/IDSA10 Clinical Practice Guidelines for CDI guide infection 
diagnosis and management in adult and pediatric patients. Guidelines currently 
recommend that clinicians discontinue therapy with inciting antimicrobial agents, which 
may affect the risk of recurrence. The clinician should then evaluate the patient’s age, 
white blood cell (WBC) count, 24-hour bowel movement count, and peak serum 
creatinine (SCr) level, which help indicate the severity of CDI. It is imperative, then, to 
initiate empiric antibiotic therapy, particularly in situations with a laboratory delay.  
In accordance with the above guidelines, oral vancomycin or fidaxomicin are 
strongly recommended to treat the first episode of CDI (non-severe and severe). Oral 
metronidazole is weakly recommended in non-severe CDI if oral vancomycin or 
fidaxomicin are unavailable (Table 1.4). Regardless of severity, treatment is 
recommended for ten days. An initial episode of fulminant CDI (CDI with shock, ileus, 
or megacolon) may be treated with oral vancomycin in combination with intravenous 
metronidazole. If oral metronidazole is used for the initial episode of CDI, oral 
vancomycin may be used to treat the first recurrence. Otherwise, a prolonged and tapered 
oral vancomycin regimen or fidaxomicin are recommended for first recurrence CDI. 
Subsequent recurrences may be treated with tapered and pulsed oral vancomycin 
(Vancomycin 125 mg PO 4 times daily for 10-14 days, then 2 times daily for 7 days, then 
daily for 7 days, and then every 2-3 days for 2-8 weeks), oral vancomycin followed by 
oral rifaximin, fidaxomicin, or fecal microbiota transplantation, although the expert panel 






Table 1.4 Recommendations for the treatment of CDI10 
Clinical definition Recommended treatment 
Initial episode, non-severe Vancomycin 125 mg PO 4 times daily for 10 days 
or FDX 200 mg PO twice daily for 10 days or 
metronidazole 500 mg PO 3 times daily for 10 
days if neither prior agent is available 
Initial episode, severe Vancomycin 125 mg PO daily for 10 days or FDX 
200 mg PO twice daily for 10 days 
Initial episode, fulminant Vancomycin 500 mg PO or by nasogastric tube 
and metronidazole 500 mg IV 3 times daily; 
Vancomycin PR may be added if ileus  
First recurrence Vancomycin 125 mg 4 times daily for 10 days or 
tapered and pulsed vancomycin regimen* or FDX 
200 mg twice daily for 10 days 
Second or subsequent recurrence Tapered and pulsed vancomycin regimen* or 
vancomycin 125 mg 4 times daily for 10 days, 
followed by rifaximin 400 mg 3 times daily for 20 
days or FDX 200 mg twice daily for 10 days or 
fecal microbiota transplant** 
FDX = fidaxomicin, PO = by mouth, PR = by rectum, IV = intravenously 
*Vancomycin 125 mg PO 4 times daily for 10-14 days, then 2 times daily for 7 days, then 
daily for 7 days, and then every 2-3 days for 2-8 weeks 





BURDEN OF ILLNESS 
C. difficile is the most common cause of infectious diarrhea in healthcare settings, 
accounting for 20-30% of antibiotic-associated diarrhea cases.15,19 In a study of U.S. 
hospitalized adults, Reveles et al.20 found that CDI incidence rates increased from 4.5 to 
8.2 CDI discharges per 1,000 total adult discharges between 2001 and 2010. By 
analyzing Healthcare Cost and Utilization Project data, Lucado et al.21 found that the U.S. 
hospitals saw a 2.5-fold increase in the number of hospitalizations with any CDI 
discharge diagnosis between 2000 and 2008. CDI discharge rates increased most 
dramatically among persons aged 65 years or greater, with 5-fold the rate of discharges 
among those aged 45-64 years.15,22 During the same period, reports of CDI epidemics 
were found to occur in Canada, with mortality increasing drastically between 1997 and 
2005.23-26 Although limited C. difficile-associated disease incidence data is available 
across Europe, laboratories in thirty-four European countries estimated a CDI incidence 
of 4.1 per 10,000 patient-days per hospital (range 0.0 – 36.3) in 2008.27,28 
A particular hypervirulent C. difficile strain, characterized as North American 
pulsed-field type NAP1, as type BI by restriction enzyme analysis, and as PCR ribotype 
027 (NAP1/BI/027), has been credited partially for the rise of CDI.8 By 2008, CDI cases 
due to the NAP1/BI/027 strain were reported by hospitals in forty U.S. states and all 
Canadian provinces, becoming endemic in some North American healthcare settings.29-31 
In a survey regarding the spread of ribotype 027 in Europe, this C. difficile strain had 
been found in sixteen European countries by 2008.32 This same year, Bauer et al.28 
estimated a 5% prevalence of ribotype 027 across thirty-four European countries. More 
recently, the emergence of the ribotype 078 has been associated with disease in younger 
patients more frequently prescribed fluoroquinolones and with community-associated or 
indeterminate CDI, as compared to ribotype 027 patients in the Netherlands.33 
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OUTCOMES AND COST 
To inform policy decisions regarding prevention and treatment, an understanding 
of the health outcomes and economic impact of CDI is essential. In a retrospective 
analysis of discharge data, the overall in-hospital mortality rate was 7.1% for adult 
patients with CDI. This mortality rate increased from 6.6% in 2001 to 7.2% in 2010. 
Median hospital length of stay (LOS) remained stable across the study period, at 
approximately eight days.20 In an analysis of age group trends, elderly patients (≥65 
years) had significantly higher rates of mortality (8.8%) compared to adults (18-64 years; 
3.1%) and pediatrics (<18 years; 1.4%; p <0.0001). LOS was also highest in elderly 
patients compared to adults and pediatric (8 vs. 7 vs. 6; p<0.0001).34  
Schweiser et al.35 estimated the burden of CDI in the U.S. based on multicenter 
studies between 2000 and 2014. Compared to other hospitalized patients, those with CDI 
were found to suffer a 2.5-fold increase in mortality, based on a pooled analysis of 22 
studies. This same analysis found a mean CDI-attributable cost of the index 
hospitalization to range from $8,426 to $48,500, although only four studies of 
questionable quality were used in this analysis. Mean readmission costs were found to be 
$14,847, while mean CDI-attributable LOS was 12.3 days.  
To further evaluate the costs of CDI on the U.S. healthcare system, Zhang et al.36 
conducted a meta-analysis using studies investigating the direct medical cost associated 
with CDI hospital management. The average price of CDI case management was 
$42,316, with an average CDI-attributable cost of $21,448 in 2015 U.S. dollars. The total 
annual CDI-attributable cost in the U.S. was estimated at $6.3 billion (range $1.9-$7.0), 
with 2.4 million days of inpatient stay required each year. A significantly lower LOS and 
median cost after diagnosis has been reported in guideline-treated patients with mild-to-




CURRENT EPIDEMIOLOGY OF CDI IN CANCER PATIENTS 
 
CDI INCIDENCE IN CANCER PATIENTS 
The incidence of CDI among cancer patients is higher than the general 
population. In a study of U.S. hospitalized adults, Reveles et al. 20 found that CDI 
incidence increased from 4.5 to 8.2 CDI discharges per 1,000 total adult discharges 
between 2001 and 2010. This compares to an increase in incidence from 6.8 to 12.8 
discharges per 1,000 adult cancer discharges from 2001 to 2010 (Figure 2.1).37 A 
multicenter study of 11 cancer centers revealed a pooled CDI incidence rate twice that of 
all other U.S. patients (15.8 vs. 7.4 per 10,000 patient-days).38  
 





CDI incidence rates also vary by cancer type. In our prior work, the incidence of 
CDI in solid tumor cancer patients (6.8 discharges per 1,000 adult solid cancer 
discharges) was lower than that of hematologic cancer patients (17.3 discharges per 1,000 
adult blood cancer discharges) over the study period.37 An epidemiologic study of 
hematopoietic stem cell transplant (HSCT) patients at a tertiary care hospital revealed 
CDI rates were 9-fold higher compared to general patients, and 1.4-fold higher compared 
to other cancer patients. A small pilot study performed to compare C. difficile strains 
among HSCT, and general ward patients revealed a variety of strains among HSCT 
patients and a much more significant presence of the NAP1/BI/027 strain among non-





CDI RISK FACTORS AMONG CANCER PATIENTS 
The significantly higher rates of CDI in cancer patients may be due to several 
factors. First, lengthy or recurrent hospitalizations lend themselves to greater C. difficile 
exposure, and as many as 32% of cancer patients undergoing chemotherapy experience at 
least one hospitalization.40 Compared to non-oncology inpatients, oncology inpatients 
have also been found to have longer median LOS.40-42  Suda et al.43 found that compared 
to 26% of non-oncology patients, 36% of cancer patients experienced a LOS >7 days. In 
2009, NHDS data estimated that the average LOS for an adult primary cancer diagnosis 
was 1.6 days longer than a non-cancer diagnosis.44  
Immunosuppression due to host immunosenescence, the disease, or drug therapy 
could predispose cancer patients to clinical infection, rather than colonization, as the 
patient might not be able to mount as strong of a host response. Older age,28,41 severe 
underlying disease,28,41 and immunosuppressive therapy45,46 have all previously been 
associated with CDI. Furthermore, prior studies have found that immunosuppressed 
patients who develop CDI are at higher risk for poor clinical outcomes.47,48 In a study of 
5,594 adult patients receiving cancer treatment, CDI-related mortality was 19.7%.49 
Neutropenia was found to be an independent predictor of CDI-related mortality.49  
CDI risk by cancer type is likely also related to several factors. Patients with 
hematologic malignancies might receive antibiotics at a higher rate due to a higher 
incidence of neutropenic fever resulting from cytotoxic chemotherapy and direct effects 
on host immunity.50 Furthermore, patients with blood cancers tend to have a longer length 
of stay during hospitalizations compared to solid tumor patients.44 Lastly, blood cancers 
have the therapeutic option of HSCT. When comparing HSCT recipients versus other 
oncology patients, Chopra et al.51 reported HSCT recipients to have 1.4 times higher CDI 
rates. It is hypothesized these differences are due to chemotherapy regimens and 
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antibiotic use leading up to transplantation, in addition to a prolonged hospital stay.47,52-54 
The distinction between blood cancers versus solid cancers is of importance in CDI 
prevention and treatment. Due to the increased risk associated with hematologic 
malignancies, more diligent antimicrobial stewardship may be warranted along with 
potentially more aggressive CDI treatment.37  
Cancer patients are frequently exposed to medications and other factors that can 
alter the gut microbiota or alter the host response. The following classes of medications 
or therapies are used frequently among cancer patients and have been previously 
associated with CDI: antibiotics28,41,45,46,55, certain chemotherapeutic agents18, gastric acid 
suppressing medications41, and manipulation of the gastrointestinal tract (e.g., enteral 
feedings, enemas, stimulants).56  
Chemotherapeutic agents have been shown previously to increase the risk for 
CDI; however, most studies have been case reports or case series.48 In a retrospective 
review of patients with gynecologic malignancies treated with paclitaxel-based 
chemotherapy regimens, the risk of CDI was estimated to be 2.2% in patients receiving 
standard-dose regimens and as high as 20% in patients receiving high-dose regimens.57 
An additional study of 33 patients with primary ovarian malignancy treated with 
cisplatin-based combinations examined the incidence of CDI, finding that two patients 
(6.1%) developed severe CDI. After successful treatment, a patient developed a CDI 
relapse after a subsequent dose of cisplatin, which did not occur again after switching to a 
carboplatin alternative.58 In neutropenic patients with hematologic malignancies, CDI 
occurred in 7% of all myelosuppressive chemotherapy cycles.59 Other reports have 
associated the following chemotherapeutic agents with CDI: bleomycin, carboplatin, 
cisplatin, cyclophosphamide, cytarabine, doxorubicin, etoposide, methotrexate, 
paclitaxel, topotecan, vinblastine, vinorelbine, and 5-FU.48,52,57,58,60-69 
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PATHOPHYSIOLOGIC MECHANISMS BY WHICH CANCER INCREASES CDI RISK 
While antibiotic-associated CDI pathogenesis is well understood, this is not the 
case for chemotherapy-associated disease, as mentioned above. It has been proposed that 
similar to antibiotics, chemotherapeutic agents like methotrexate may lead to a disruption 
of gut microbiota, enabling alternative bacterial growth.70 The chemotherapeutic drugs 
methotrexate and 5-FU maintain the ability to cause severe intestinal mucositis since 
apoptosis is induced through inhibition of DNA and RNA synthesis.48 In rat models, 
methotrexate was shown to disrupt intestinal protein metabolism, increase proteolysis, 
and enhance cytokine response, which could promote C. difficile pathogenesis.48,71 DNA 
topoisomerase inhibitors, such as irinotecan and topotecan, can also result in severe 
mucositis, but an increase in CDI has never been illustrated.48 
Other proposed mechanisms of increased pathogenesis in the cancer population 
include inflammatory changes induced by chemotherapy, necrosis in the intestinal tract 
that promotes an anaerobic environment, and delayed reestablishment of normal gut 
microbiota increasing the possibility of relapse. The exact pathogenesis is unclear at this 
point. Confounders present due to the disease itself and concomitant treatments make 





TREATMENT OF CDI IN CANCER PATIENTS 
At this point, treatment of CDI in cancer patients follows the same guidelines as 
the general population. The SHEA-IDSA Clinical Practice Guidelines for CDI provide 
guidance for the diagnosis and management of CDI in adult patients.10 Guidelines 
currently recommend that clinicians discontinue therapy with inciting antimicrobial 
agents, which may affect the risk of recurrence. Oncology specialists maintain the 
additional consideration of chemotherapeutic agents, which may also have an influence. 
The clinician then evaluates the patient’s age, WBC count, and peak serum creatinine 
level, which help indicate the severity of CDI. Assessing severity by WBC count presents 
a challenge in patients who frequently suffer from neutropenia. 
Following the general guidelines, metronidazole has fallen out of favor due to 
recent clinical trial data indicating inferior effectiveness compared to vancomycin. In a 
randomized controlled trial, CDI treatment success was significantly higher in patients 
treated with oral vancomycin (81%) compared to metronidazole (73%) (p=0.02).72 
Comparative efficacies of metronidazole and vancomycin have not been studied in cancer 
patients, but the response rate to oral metronidazole was found to be 90.9% in a cohort of 
neutropenic patients with hematologic malignancies.59  
The clinical practice guidelines now recommend oral vancomycin or fidaxomicin 
as first-line therapy for all patients; however, recent clinical trial data support the use of 
fidaxomicin in cancer patients. In an analysis of Phase 3 fidaxomicin clinical trial data, 
clinical cure of CDI was higher (though not quite statistically significant) in patients 
treated with fidaxomicin compared to vancomycin (OR 2.0; p=0.065). Importantly, risk 
for recurrence was significantly lower among fidaxomicin-treated patients (OR 0.37; 
p=0.018).73 Despite the higher drug acquisition costs, using fidaxomicin as first-line 




As a common and increasingly burdensome healthcare-associated infection, CDI 
has been the target of focused epidemiological studies and infection control strategies.15,20 
Recent data has also demonstrated the increased incidence of CDI among cancer 
patients.37,39 In particular, rates of CDI among patients with hematologic cancers are 
alarming, and limited evidence supports poorer outcomes in this population compared to 
the general population and overall cancer population.20,37 It is apparent, however, that 
sufficient data to assess risk, predict outcomes, and provide optimal care to this 
population are lacking.37,48 Although much evidence supports the biological plausibility 
of cancer patients suffering an increased risk of CDI, much of the reported evidence has 
not been corroborated by large, high-quality observational studies or clinical trials.  
Knowledge of the risk of CDI among patients diagnosed with cancer represents a 
fundamental gap in knowledge. Although prior studies have highlighted the incidence of 
CDI among cancer patients, a quantifiable risk of CDI associated with disease allows 
cancer patients to be more readily identified as a high-risk population in whom 
antimicrobial stewardship and other infection control processes should be targeted. These 
data could also serve as justification for further work for elucidating the mechanisms 
behind these associations.  
The limited cancer-specific treatment data precludes the use of evidence-based 
management strategies, particularly considering the lack of high quality data supporting 
the risk of CDI among patients with a cancer diagnosis or undergoing chemotherapeutic 
treatment. Further studies are needed to evaluate the comparative-effectiveness of CDI-
targeted antibiotic therapies in this high-risk population.  
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In the future, clinicians may tailor CDI therapy for this population specifically. 
For example, clinicians might choose a more aggressive or costly therapy in cancer 
patients to improve clinical outcomes. Despite the importance of this knowledge, 








SPECIFIC AIMS AND HYPOTHESES 
 
SPECIFIC AIM 1: DEFINE THE RISK OF CDI ASSOCIATED WITH A CANCER DIAGNOSIS, 
COMPARED TO A GROUP OF NON-CDI CONTROLS 
Hypothesis 1.1: The risk of CDI is greater in patients with a cancer diagnosis. 
Hypothesis 1.2: Patients with hematologic malignancy will have a higher risk of CDI 
compared to non-hematologic cancers. 
 
SPECIFIC AIM 2: COMPARE CDI CLINICAL OUTCOMES OF PATIENTS WITH AND 
WITHOUT CANCER 
Hypothesis 2.1: CDI patients with cancer will have higher risk of 30-day mortality, 
60-day CDI recurrence, and hospital LOS compared to non-cancer patients. 
 
SPECIFIC AIM 3: COMPARE CDI CLINICAL OUTCOMES AMONG PATIENTS WHO RECEIVE 
METRONIDAZOLE OR VANCOMYCIN 
Hypothesis 3.1: Patients who receive oral metronidazole will have higher risk for 30-
day mortality, 60-day CDI recurrence, and hospital LOS compared to patients who 








This was a retrospective study of patients with their first occurrence of CDI 
receiving care at any inpatient VHA facility in the United States. Aim 1 follows a case-
control design, whereas aims 2 and 3 are retrospective cohort studies. Data for this study 
were obtained from the VA Informatics and Computing Infrastructure (VINCI), which 
includes administrative, clinical, laboratory, and pharmacy data repositories that are 
linked using unique patient identifiers. This study was approved by the Institutional 
Review Boards at UT Health San Antonio and the South Texas Veterans Health Care 
System Research and Development Committee.  
 
STUDY POPULATION 
The CDI cohort was created by identifying patients 18-89 years old who had any 
inpatient or outpatient International Classification of Diseases, 9th Revision, Clinical 
Modification (ICD-9-CM) code for CDI (008.45) plus a positive CDI stool test (e.g., 
toxin enzyme immunoassay or nucleic acid amplification test ± glutamate dehydrogenase 
antigen test) during the visit or within 7 days of the visit from October 1, 2002 through 
September 30, 2014. CDI patients were also required to have received active CDI therapy 
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(oral vancomycin, metronidazole, fidaxomicin) during the CDI encounter. Patients with 
an ICD-9-CM code for CDI (008.45) in the year prior to study inclusion were excluded. 
A control group was created by identifying a random sample of VHA patients without a 
CDI ICD-9-CM code for the duration of the study period and matching 2:1 (control to 
CDI) by treatment setting (inpatient or outpatient) and fiscal year of visit.  
 
INDEPENDENT VARIABLES 
Cancer diagnosis in the year prior to cohort inclusion was defined using ICD-9-
CM codes and was coded overall and by cancer type (Table 4.1).  
 
Table 4.1 Cancer diagnosis ICD-9-CM codes 
Cancer type ICD-9-CM codes 
Malignant neoplasm of the lip, oral cavity, and pharynx 140-149.X 
Malignant neoplasm of the digestive organs and peritoneum 150-159.X 
Malignant neoplasm of the respiratory and intrathoracic organs 160-165.X 
Malignant neoplasm of the bone, connective tissue, skin, and breast 170-176.X 
Malignant neoplasm of the genitourinary organs 179-189.X 
Malignant neoplasm of other and unspecified sites 190-199.X 
Malignant neoplasm of lymphatic and hematopoietic tissue 200-208.XX 
Neuroendocrine tumors 209.XX 
 
 
Patient demographics included age, sex, race, and ethnicity. Charlson 
comorbidities and other relevant diagnoses, as defined by ICD-9-CM codes, were 
collected for the year prior to the CDI encounter (Table 4.2). The Charlson comorbidity 





Table 4.2. Study comorbidity definitions 




Myocardial infarction 410, 412 
Congestive heart failure 428 
Peripheral vascular disease 441, 443.9, 785.4, V43.4 
Cerebrovascular disease 430-438 
Dementia 290 
COPD 490-496, 500-505, 506.4 
Rheumatologic disease 710.0-710.1, 710.4, 714.0-714.2, 714.81, 725 
Peptic ulcer disease 531.0-531.9, 532.0-532.9, 533.0-533.9, 534.0-534.9 
Liver disease 571.2, 571.4, 571.5, 571.6, 572.2-572.8, 456.0-456.21 
Diabetes  250.0-250.3, 250.4, 250.5, 250.6, 250.7, 250.8, 250.9 
Renal disease  582, 583, 585, 586, 588 
HIV/AIDS 42-44, V08 
Bacteremia 790.7 
Pneumonia 480.0-483.99, 485–487 
Skin infection 680-686 
Endocarditis 421.0, 421.1, 421.9, 424.9 
Urinary tract infection 590-599 
Device-related infection 996.31, 996.62, 996.64, 999.31 
Acute respiratory infection 460-466 
GERD 530.11, 530.81 
Transplant V42, E878.0 
Inflammatory bowel disease 555, 556 
Irritable bowel syndrome 564.1 
Bacteremia 790.7 
Pneumonia 480.0-483.99, 485–487 
Skin infection 680-686  
Intra-abdominal infection 540–543, 562, 567, 569, 574–577 
Urinary tract infection 590-599 
Device-related infection 996.31, 996.62, 996.64, 999.31 
Acute respiratory infection 460-466 
Endocarditis 421.0, 421.1, 421.9, 424.9 
Shock 639.5, 785.52, 785.59 
Sepsis/septicemia 020.2, 038.0-038.9, 995.91, 995.92 
Prolonged ileus 560.1 
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Megacolon 558.2, 564.7 
Acute renal failure 584, 586 
Principal CDI was defined as ICD-9-CM code 008.45 in the first position. This 
often indicates that CDI was the primary contributor to hospitalization. Secondary CDI 
was defined as ICD-9-CM code 008.45 in any position except first. CDI was also 
characterized by type. Community-onset CDI (CO-CDI) was defined based upon the 
presence of CDI therapy initiated in the outpatient setting or on days 1 or 2 of 
hospitalization. Community-onset, healthcare facility-associated CDI (CO-HCFA-CDI) 
was defined the same way, with the addition of a hospitalization in the prior 90 days. 
Lastly, healthcare facility-onset CDI was defined as CDI therapy beginning on day 3 or 
later of hospitalization.  
Concomitant infections were collected that occurred during an encounter 
(between CDI episode start date and end of CDI therapy for CDI patients and during 
hospitalization for control group), including: bacteremia, pneumonia, skin infection, 
intra-abdominal infection, urinary tract infection, device-related infection, endocarditis, 
and acute respiratory infection. Other markers of CDI severity that occurred during an 
encounter were also captured, including sepsis/septicemia, shock, megacolon, prolonged 
ileus, perforated intestine, acute renal failure, and ICU admission.  
Prior and concomitant non-CDI antibiotics (excludes oral vancomycin, 
metronidazole, fidaxomicin, rifaximin, and nitazoxanide), gastric acid suppressant (GAS) 
drugs (antacids, histamine-2 receptor antagonists [H2RAs], proton pump inhibitors 
[PPIs]), and narcotics were collected. Prior use was defined as any use in the 90 days 
prior to the encounter and concomitant use was defined as any use during or within 60 
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days following the encounter. The 60-day follow-up period for concomitant medication 
use was chosen because this time period is likely to capture the majority of medication 
use between initial CDI and recurrence; recurrent CDI is most common within one to 
three weeks post-treatment discontinuation, but late recurrences are also common.76 
For aim 3, CDI therapy was defined as receipt of either oral vancomycin or 
metronidazole (intravenous or oral). Fidaxomicin was used very infrequently (<1% of the 
population); therefore, comparative-effectiveness studies with this antibiotic were not 
feasible. For comparisons between metronidazole and vancomycin, patients were limited 
to those who received only monotherapy with one of these agents.  
 
DEPENDENT VARIABLES 
For aim 1 only, CDI was the primary dependent variable. CDI was defined as stated in 
the study population section and was compared to a non-CDI control group.  
All-cause 30-day mortality was our primary outcome for aims 2 and 3. Hospital LOS was 
also assessed. We defined hospital LOS as a dichotomous (hospital LOS ≥14 versus <14 days) to 
facilitate logistic regression modeling. Another important dependent variable included CDI 
recurrence. Recurrent CDI typically occurs within one to three weeks post-treatment 
discontinuation, but late recurrences, occurring up to 60 days post-treatment discontinuation, are 
frequent. The mean relapse time is approximately 14.5 days, whereas mean reinfection time is 
42.5 days.76 We chose 60-day recurrence as our primary dependent variable because it is likely to 
capture the majority of CDI recurrences. This definition and has been used as the primary 
outcome in other studies evaluating CDI recurrence risk.77 
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DATA AND STATISTICAL ANALYSIS 
Data extraction and variable creation were conducted using SAS Version 9.2® 
(SAS Corp., Cary, NC, USA). All other data and statistical analyses were conducted 
using JMP 10.0® (SAS Corp., Cary, NC, USA).  
 
Specific Aim 1 
In this case-control design that included all CDI patients and controls, all 
independent and dependent variables were first presented descriptively. Continuous 
variables were presented as means, standard deviations, medians, and interquartile 
ranges. Categorical variables were presented as the number and percentage of subjects in 
each category. For baseline characteristics (e.g., gender, race, ethnicity), we included a 
missing category. Other variables that were absent from the medical chart (e.g., 
comorbidities, medications) were assumed to have not occurred.  
We first compared independent variables, including cancer diagnoses, between 
groups using the chi-square test. Next, we conducted a multivariable logistic regression 
test using CDI as the dependent variable, cancer as the independent variable, and 28 
covariates. Covariates included age, gender, race & ethnicity, fiscal year of visit, 
hypertension, dyslipidemia, obesity, myocardial infarction, paraplegia/hemiplegia, 
congestive heart failure, perivascular disease, cerebrovascular disease, dementia, chronic 
obstructive pulmonary disease, rheumatologic disease, liver disease, diabetes, renal 
disease, HIV/AIDS, GERD, transplant, inflammatory bowel diseases, irritable bowel 
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syndrome, prior antibiotics, prior gastric acid suppressants, prior narcotics, prior anti-
diarrheals, and prior bowel prep. To assess the risk of CDI by cancer type, we repeated 
the above procedures to assess each cancer type as an independent risk factor for CDI.  
 
Specific Aim 2 
 In this retrospective cohort study, the study population was limited to CDI 
patients only (exclusive of controls). Health outcomes, including 30-day mortality, 
hospital LOS ≥14 days, and 60-day CDI recurrence were compared between CDI patients 
with and without cancer using the chi-square test. Next, we conducted a series of 
multivariable logistic regression tests using each health outcome as the dependent 
variable, cancer as the independent variable, and 58 covariates. Covariates included age, 
gender, race & ethnicity, fiscal year of visit, principal CDI, CDI surveillance definition, 
hypertension, dyslipidemia, obesity, myocardial infarction, congestive heart failure, 
perivascular disease, cerebrovascular disease, paraplegia/hemiplegia, dementia, chronic 
obstructive pulmonary disease, rheumatologic disease, liver disease, diabetes, renal 
disease, HIV/AIDS, GERD, transplant, inflammatory bowel diseases, irritable bowel 
syndrome, prior medications (antibiotics, gastric acid suppressants, narcotics, anti-
diarrheals, prior bowel prep), concomitant infections (bacteremia, skin infection, 
pneumonia, UTI, intra-abdominal infection, endocarditis, respiratory tract infection), 
individual severity indicators, and concomitant medications (antibiotics, gastric acid 
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suppressants, narcotics, anti-diarrheals, prior bowel prep), including CDI therapies 
(metronidazole, vancomycin, fidaxomicin, rifaximin, nitazoxanide, probiotics).  
 
Specific Aim 3 
 In this retrospective cohort study, the study population was limited to CDI 
patients with cancer only and those who received monotherapy with either metronidazole 
or oral vancomycin. Health outcomes, including 30-day mortality, hospital LOS ≥14 
days, and 60-day CDI recurrence were compared between CDI patients with and without 
cancer using the chi-square test for dichotomous outcomes and the Wilcoxon rank sum 
test for hospital LOS. Next, we conducted a series of multivariable logistic regression 
tests using each health outcome as the dependent variable, cancer as the independent 
variable, and 52 covariates. Covariates included age, gender, race & ethnicity, fiscal year 
of visit, principal CDI, CDI surveillance definition, hypertension, dyslipidemia, obesity, 
myocardial infarction, congestive heart failure, perivascular disease, cerebrovascular 
disease, paraplegia/hemiplegia, dementia, chronic obstructive pulmonary disease, 
rheumatologic disease, liver disease, diabetes, renal disease, HIV/AIDS, GERD, 
transplant, inflammatory bowel diseases, irritable bowel syndrome, prior medications 
(antibiotics, gastric acid suppressants, narcotics, anti-diarrheals, prior bowel prep), 
concomitant infections (bacteremia, skin infection, pneumonia, UTI, intra-abdominal 
infection, endocarditis, respiratory tract infection), individual severity indicators, and 
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concomitant medications (antibiotics, gastric acid suppressants, narcotics, anti-diarrheals, 
prior bowel prep).  
Lastly, we validated the results of the logistic regression model using a propensity 
score-matched cohort. Specifically, logistic regression was used to generate propensity 
scores using the treatment (metronidazole versus vancomycin) as the dependent variable 
and the following 28 covariates: Covariates included age, gender, race & ethnicity, fiscal 
year of visit, hypertension, dyslipidemia, obesity, myocardial infarction, congestive heart 
failure, perivascular disease, cerebrovascular disease, paraplegia/hemiplegia, dementia, 
chronic obstructive pulmonary disease, rheumatologic disease, liver disease, diabetes, 
renal disease, HIV/AIDS, GERD, transplant, inflammatory bowel diseases, irritable 
bowel syndrome, and prior medications (antibiotics, gastric acid suppressants, narcotics, 
anti-diarrheals, prior bowel prep). Propensity scores were then matched 1:1 using nearest 
neighbor matching without replacement and a caliper of 0.001. Following matching, 









GENERAL POPULATION CHARACTERISTICS 
Overall 26,149 patients met study inclusion criteria for CDI and another 52,298 
were included as non-CDI controls. Table 5.1 describes the patients’ baseline 
characteristics. CDI patients were predominately elderly (median age 67 years), male 
(95.9%), and White (71.8%). The median (IQR) Charlson comorbidity score was 3 (1-5). 
The most common comorbidities included: hypertension (77.5%), diabetes (40.3%), 
dyslipidemia (54.7%), COPD (37.7%), and cancer (26.6%). CDI patients were commonly 
exposed to other medications prior to the episode including non-CDI antibiotics (55.4%) 
and GAS drugs (55.7%). 
Given the large sample size, there were statistically significant differences 
between the CDI and control cohort for all independent variables tested. Patients with 
CDI tended to have higher rates of comorbidities and medication use prior to cohort 
inclusion, as seen in the higher median Charlson score in the CDI cohort compared to the 
control group (3 vs. 1; p<0.0001). Other notable differences included older age and more 
prior hospitalizations among CDI patients and a higher proportion of cardiovascular, 
metabolic, inflammatory diseases. Prior medication use was also significantly more 
common among CDI patients compared to controls.  
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Age (years), median (IQR) 67 (60-78) 62 (53-72) <0.0001 
Male sex, % 95.9 93.9 <0.0001 
Hispanic ethnicity, % 5.3 6.0 <0.0001 
White race, % 71.8 69.0 <0.0001 
Prior hospitalization, % 49.0 16.0 <0.0001 
Hypertension 77.5 56.8 <0.0001 
Dyslipidemia 54.7 44.6 <0.0001 
Obesity 16.4 14.7 <0.0001 
Myocardial infarction 11.1 3.7 <0.0001 
Congestive heart failure 26.1 8.6 <0.0001 
Peripheral vascular disease 18.8 8.5 <0.0001 
Cerebrovascular disease 19.2 9.5 <0.0001 
Dementia 3.8 1.5 <0.0001 
COPD 37.7 20.5 <0.0001 
Peptic ulcer disease 4.6 1.6 <0.0001 
Liver disease 7.0 2.2 <0.0001 
Diabetes 40.3 26.7 <0.0001 
Renal disease 27.7 8.1 <0.0001 
Cancer 26.6 15.3 <0.0001 
      Metastasis 7.7 2.9 <0.0001 
      Oral 0.0 0.9 <0.0001 
      Digestive 6.0 3.2 <0.0001 
      Respiratory 4.7 3.2 <0.0001 
      Bone, skin, breast 5.2 3.4 <0.0001 
      Genitourinary 11.0 7.4 <0.0001 
      Lymphatic/hematologic 2.9 1.5 <0.0001 
      Neuroendocrine 0.2 0.1 0.0003 
      Other 6.9 3.8 <0.0001 
HIV/AIDS 1.8 0.8 <0.0001 
GERD 26.7 23.1 <0.0001 
Transplant 1.9 < 0.1 <0.0001 
Inflammatory bowel disease 2.2 0.8 <0.0001 
Irritable bowel syndrome 1.1 0.9 0.0018 
Charlson score, median (IQR) 3 (2-6) 1 (0-3) <0.0001 
Prior antibiotics 55.4 21.5 <0.0001 
Prior GAS drugs 55.7 31.2 <0.0001 
Prior narcotics 38.0 21.2 <0.0001 
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SPECIFIC AIM 1: DEFINE THE RISK OF CDI ASSOCIATED WITH A CANCER DIAGNOSIS, 
COMPARED TO A GROUP OF NON-CDI CONTROLS 
Hypothesis 1.1: The risk of CDI is greater in patients with a cancer diagnosis. 
 
 In bivariable analyses, the proportion of patients with a prior diagnosis of cancer 
was significantly higher in the CDI cohort (26.6%) compared to the control cohort 
(15.3%) (Table 5.1). In the multivariable model, cancer was an independent predictor of 
CDI (OR 1.41; 95% CI 1.35-1.47); therefore, we accept our alternative hypothesis that 
the risk of CDI is greater in patients with cancer. Despite this, cancer was not as strong of 
a predictor compared to other factors. A diagnosis code for transplant was the strongest 
predictor of CDI (OR 39.9; 95% CI 23.26-68.56), followed by paraplegia/hemiplegia 
(OR 3.73; 95% CI 3.30-4.22), inflammatory bowel disease (OR 3.69; 95% CI 3.20-4.26), 
liver disease (OR 2.96; 95% CI 2.72-3.22), HIV/AIDS (OR 2.73; 95% CI 2.34-3.17), and 





Table 5.2 Independent risk factors for CDI 
 
Characteristic OR (95% CI) 
Transplant 39.9 (23.26 - 68.56) 
Paraplegia/hemiplegia 3.73 (3.30 - 4.22) 
Inflammatory bowel disease 3.69 (3.20 - 4.26) 
HIV/AIDS 2.73 (2.34 - 3.17) 
Liver disease 2.96 (2.72 - 3.22) 
Prior antibiotics 2.32 (2.23 - 2.42) 
Renal disease 2.17 (2.07 - 2.28) 
Prior Hospitalization 2.05 (1.97 - 2.14) 
Peptic Ulcer Disease 2.05 (1.85 - 2.27) 
Dementia 1.70 (1.52- 1.90) 
Congestive heart failure 1.64 (1.56 - 1.73) 
Myocardial Infarction 1.54 (1.43 - 1.65) 
Irritable bowel syndrome 1.51 (1.27 - 1.78) 
Rheumatologic disease 1.45 (1.28 - 1.63) 
COPD 1.42 (1.37 - 1.48) 
Cancer 1.41 (1.35 - 1.47) 
Hypertension 1.39 (1.33 - 1.45) 
Age > 65 years 1.38 (1.33 - 1.44) 
Peripheral vascular disease 1.30 (1.23 - 1.37) 
Cerebrovascular disease 1.27 (1.20 - 1.33) 
Prior GAS 1.18 (1.14 - 1.23) 
Prior narcotics 1.16 (1.12 - 1.21) 
Female sex 1.10 (1.01 - 1.19) 
non-Hispanic ethnicity 1.10 (1.02 - 1.19) 
White race 1.07 (1.02 - 1.12) 




Hypothesis 1.2: Patients with hematologic malignancy will have a higher risk of CDI 
compared to non-hematologic cancers. 
 
In bivariable analysis, the proportion of patients with each cancer types (with the 
exception of oral cancers) was higher among the CDI cohort compared to the control 
cohort (Table 5.2). In multivariable models, cancer with metastasis was the strongest, 
statistically significant predictor of CDI, followed by lymphatic/hematologic cancers 
(Table 5.3). Interestingly, genitourinary, respiratory, and other cancers were inverse 
predictors of CDI. 
 
Table 5.3 Independent risk factors for CDI by cancer type 
 
Characteristic OR (95% CI) 
Metastasis 4.68 (4.02-5.45) 
Neuroendocrine 1.38 (0.83-2.30) 
Lymphatic/hematologic 1.27 (1.03-1.31) 
Digestive 1.06 (0.97-1.16) 
Bone, skin, breast 1.02 (0.93-1.11) 
Genitourinary 0.93 (0.87-0.99) 
Respiratory 0.75 (0.68-0.83) 
Other 0.32 (0.27-0.37) 
Oral* -- 
												*Removed due to model instability 




SPECIFIC AIM 2: COMPARE CDI CLINICAL OUTCOMES OF PATIENTS WITH AND 
WITHOUT CANCER 
Hypothesis 2.1: Patients with cancer will have higher risk of 30-day mortality, 60-day 
CDI recurrence, and hospital LOS compared to non-cancer patients. 
 
 Among patients with CDI, 7,538 (28.8%) were diagnosed with cancer. Patients 
with cancer were more likely to be older, have HCFO-CDI, and have more comorbidity 
(Table 5.4). CDI severity was relatively similar between groups. Prior and concomitant 
medication use was significantly more common among patients with cancer.   
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Table 5.4 Baseline characteristics among CDI patients with and without cancer 
 





Age (years), median (IQR) 66 (59-78) 70 (63-79) <0.0001 
Male sex, % 95.3 97.3 <0.0001 
Race & ethnicity, %   0.0007 
    Non-Hispanic White 66.1 66.6  
    Non-Hispanic Black 21.2 20.8  
    Hispanic 5.7 4.7  
    Other 4.3 4.6  
    Missing 2.8 3.3  
Principal CDI diagnosis, % 28.9 26.3 <0.0001 
CDI type, %   <0.0001 
    CA-CDI 21.2 14.4  
    CO-HCFA-CDI 20.0 21.9  
    HCFO-CDI 58.8 63.7  
Comorbidities, %    
    Hypertension 77.4 78.3 0.0638 
    Dyslipidemia 53.9 56.2 0.0004 
    Obesity 17.0 15.3 0.0002 
    Myocardial infarction 11.8 10.2 <0.0001 
    Congestive heart failure 28.0 23.0 <0.0001 
    Peripheral vascular disease 20.1 17.8 <0.0001 
    Cerebrovascular disease 20.1 18.0 <0.0001 
    Dementia 4.0 3.1 <0.0001 
    COPD 36.5 41.3 <0.0001 
    Rheumatologic disease 2.8 2.6 0.3770 
    Peptic ulcer disease 4.5 5.0 0.0522 
    Liver disease 7.6 6.0 <0.0001 
    Diabetes 42.8 36.8 <0.0001 
    Renal disease 28.6 27.6 0.0797 
    HIV/AIDS 2.1 1.4 0.0002 
    GERD 26.7 28.1 0.0167 
    Transplant 1.9 2.2 0.1694 
    Inflammatory bowel disease 2.8 1.6 <0.0001 
    Irritable bowel syndrome 1.3 0.7 <0.0001 




Table 5.4 Baseline characteristics among CDI patients (continued) 
 





Concomitant infections, %    
    Bacteremia 6.8 7.4 0.0826 
    Pneumonia 22.6 24.1 0.0038 
    Skin infection 12.0 8.2 <0.0001 
    Intra-abdominal infection 6.3 5.3 0.0007 
    Device-related infection 3.3 3.3 0.7436 
    Acute respiratory infection 3.5 3.2 0.1708 
    Endocarditis 1.2 0.7 0.0004 
    Urinary tract infection 1.3 3.0 <0.0001 
CDI severity indicators, %    
    ICU admission 3.4 3.0 0.0446 
    Sepsis/septicemia 17.3 18.7 0.0046 
    Shock 5.2 5.1 0.8410 
    Acute renal failure 30.7 30.9 0.6496 
    Megacolon 0.3 0.3 0.8332 
    Prolonged ileus 3.9 4.5 0.0130 
    Perforated intestine 0.5 0.7 0.0145 
    WBC ≥15,000 cells/µL 38.4 41.1 <0.0001 
    CRP ≥160 mg/L 1.8 1.4 0.0072 
    Albumin <2.5 g/dL 30.9 37.6 <0.0001 
Medications, %    
    Prior antibiotics 54.4 62.5 <0.0001 
    Prior GAS drugs 54.9 62.2 <0.0001 
    Prior narcotics 35.3 47.8 <0.0001 
    Prior anti-diarrheals 6.7 10.1 <0.0001 
    Prior bowel prep 14.0 19.9 <0.0001 
    Concomitant antibiotics 73.7 78.8 <0.0001 
    Concomitant GAS drugs 78.0 82.2 <0.0001 
    Concomitant narcotics 47.7 59.7 <0.0001 
    Concomitant anti-diarrheals 10.5 13.3 <0.0001 





In bivariable analyses, patients with cancer experienced higher rates of 30-day 
mortality (29.0% vs. 17.7%, p<0.0001) compared to non-cancer patients (Figure 5.1). 
There was not a significant difference in 60-day recurrence (16.2% vs. 16.0%, p=0.7960) 
or hospital LOS ≥14 days (51.3% vs. 48.5%, p=0.3827) between cancer and non-cancer 
patients. In multivariable models, cancer was a significant predictor of 30-day mortality 
(OR 1.44; 95% CI 1.33-1.55), but not of 60-day recurrence (OR 1.00; 95% CI 0.91-1.13) 
or hospital LOS ≥14 days (OR 0.99; 95% CI 0.92-1.12).  
When limited to CDI patients with cancer, the majority of patients were 
diagnosed with a solid cancer (89.9%) compared to hematologic malignancy (10.1%). In 
bivariable analyses, hematologic malignancy patients experienced higher rates of 30-day 
mortality (35.1% vs. 28.3%, p<0.0001) compared to solid tumor patients (Figure 5.1). 
There was not a significant difference in 60-day recurrence (19.1% vs. 15.8%, p=0.4532) 
or hospital LOS ≥14 days (54.5% vs. 51.0%, p=0.3235) between hematologic malignancy 
and solid tumor patients. In multivariable models, hematologic malignancy was a 
significant predictor of 30-day mortality (OR 1.85; 95% CI 1.56-2.19), but not of 60-day 






















30-day mortality 60-day recurrence LOS >14 days 
No cancer Cancer Solid tumor Hematologic malignancy 
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SPECIFIC AIM 3: COMPARE CDI CLINICAL OUTCOMES AMONG PATIENTS WHO RECEIVE 
METRONIDAZOLE OR VANCOMYCIN 
Hypothesis 3.1: Patients who receive oral metronidazole will have higher risk for 30-day 
mortality, 60-day CDI recurrence, and hospital LOS compared to patients who receive 
oral vancomycin. 
 
A total of 3,968 (80.6%) CDI patients received oral metronidazole monotherapy 
and 953 (19.4%) received oral vancomycin monotherapy (Table 5.5). Prior to propensity 
score matching, patients treated with vancomycin were more likely to have a principal 
CDI diagnosis and have community-onset CDI. Importantly, vancomycin-treated patients 
had more severe disease, as indicated by higher rates of sepsis, shock, acute renal failure, 
complications, and abnormal laboratory values.  
In the unmatched cohorts, 30-day mortality was similar between patients treated 
with metronidazole (27.2%) compared to vancomycin (29.3%) (OR 1.12; 95% CI 0.91-
1.36) (Figure 5.2). Interestingly, vancomycin was associated with a significantly higher 
risk of 60-day CDI recurrence (23.3% vs. 13.7%; OR 1.70; 95% CI 1.27-2.27) and 











Age (years), median (IQR) 70 (63-79) 69 (63-79) 0.9171 
Male sex, % 96.9 98.0 0.0465 
Race & ethnicity, %   0.0052 
    Non-Hispanic White 66.3 65.6  
    Non-Hispanic Black 20.7 19.5  
    Hispanic 4.1 7.0  
    Other 5.5 4.4  
    Missing 3.4 3.5  
Principal CDI diagnosis, % 23.2 29.2 0.0002 
CDI type, %   <0.0001 
    CA-CDI 15.7 20.7  
    CO-HCFA-CDI 23.1 28.9  
    HCFO-CDI 61.2 50.5  
Comorbidities, %    
    Hypertension 77.2 79.0 0.2392 
    Dyslipidemia 54.9 60.7 0.0014 
    Obesity 15.1 14.9 0.8641 
    Myocardial infarction 9.4 9.7 0.7920 
    Congestive heart failure 22.4 21.1 0.3878 
    Peripheral vascular disease 16.4 18.5 0.1349 
    Cerebrovascular disease 17.1 18.2 0.4257 
    Dementia 3.2 2.4 0.2195 
    COPD 41.7 39.8 0.2680 
    Rheumatologic disease 2.4 2.6 0.6832 
    Peptic ulcer disease 5.3 5.0 0.7029 
    Liver disease 5.2 7.3 0.0110 
    Diabetes 35.5 38.4 0.0900 
    Renal disease 25.1 31.8 <0.0001 
    Solid tumor 90.7 89.3 0.1916 
    Metastases 28.4 27.0 0.3917 
    HIV/AIDS 1.2 1.6 0.3467 
    GERD 27.4 31.4 0.0150 
    Transplant 1.8 2.9 0.0266 
    Inflammatory bowel disease 1.3 2.3 0.0266 
    Irritable bowel syndrome 0.8 0.3 0.1020 
Charlson score, median (IQR) 6 (3-9) 6 (4-9) 0.0942 
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Concomitant infections, %    
    Bacteremia 5.8 5.2 0.4695 
    Pneumonia 20.8 21.1 0.8515 
    Skin infection 7.3 5.2 0.0187 
    Intra-abdominal infection 4.8 3.0 0.0142 
    Device-related infection 2.6 2.5 0.8920 
    Acute respiratory infection 2.8 1.0 0.0005 
    Endocarditis 0.4 0.5 0.6150 
    Urinary tract infection 2.9 2.2 0.2122 
CDI severity indicators, %    
    ICU admission 2.9 2.9 0.9143 
    Sepsis/septicemia 11.9 26.1 <0.0001 
    Shock 2.4 8.8 <0.0001 
    Acute renal failure 25.2 35.7 <0.0001 
    Megacolon 0.1 0.3 0.0926 
    Prolonged ileus 3.2 5.9 0.0002 
    Perforated intestine 0.3 0.9 0.0138 
    WBC ≥15,000 cells/µL 33.9 50.9 <0.0001 
    CRP ≥160 mg/L 0.8 2.0 0.0037 
    Albumin <2.5 g/dL 30.9 47.7 <0.0001 
Medications, %    
    Prior antibiotics 61.2 62.2 0.5457 
    Prior GAS drugs 60.6 61.8 0.4969 
    Prior narcotics 45.9 47.5 0.3615 
    Prior anti-diarrheals 9.5 9.1 0.7411 
    Prior bowel prep 19.1 22.5 0.0201 
    Concomitant antibiotics 75.7 76.1 0.7855 
    Concomitant GAS drugs 80.3 79.7 0.6797 
    Concomitant narcotics 57.1 57.2 0.9413 
    Concomitant anti-diarrheals 12.7 9.9 0.0138 
    Concomitant bowel prep 21.1 23.7 0.0801 
CDI therapies, %    
    Fidaxomicin 0.02 0.9 <0.0001 
    Rifaximin 0.6 1.3 0.0241 
    Probiotics 18.0 18.4 0.7766 
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Figure 5.2 Comparative-effectiveness of metronidazole and vancomycin on CDI health 





After propensity score matching, a total of 800 CDI patients were included each 
in the metronidazole and vancomycin groups (Table 5.6). Matching resulted in 
statistically similar baseline characteristics, comorbidities, CDI severity, and medication 
use.  
In the matched cohorts, 30-day mortality was similar between patients treated 
with metronidazole (26.3%) compared to vancomycin (27.8%) (OR 1.08; 95% CI 0.87-
1.34) (Figure 5.3). Similar to the unmatched cohorts, vancomycin was associated with a 
significantly higher risk of 60-day CDI recurrence (23.1% vs. 15.2%; OR 1.67; 95% CI 


















Age (years), median (IQR) 69 (63-79) 69 (63-79) 0.888 
Male sex, % 98.0 97.6 0.608 
Race & ethnicity, %   0.068 
    Non-Hispanic White 62.9 66.4  
    Non-Hispanic Black 23.8 18.1  
    Hispanic 5.6 6.9  
    Other 3.9 4.9  
    Missing 3.9 3.8  
Principal CDI diagnosis, % 27.1 28.1 0.695 
CDI type, %   0.314 
    CA-CDI 20.8 19.8  
    CO-HCFA-CDI 25.3 28.6  
    HCFO-CDI 54.0 51.6  
Comorbidities, %    
    Hypertension 78.6 78.6 1.000 
    Dyslipidemia 56.4 60.0 0.171 
    Obesity 14.8 15.1 0.833 
    Myocardial infarction 10.1 9.5 0.674 
    Congestive heart failure 20.4 21.4 0.623 
    Peripheral vascular disease 17.3 18.0 0.694 
    Cerebrovascular disease 20.3 17.0 0.095 
    Dementia 2.3 2.1 0.864 
    COPD 40.8 39.1 0.507 
    Rheumatologic disease 2.8 2.8 1.000 
    Peptic ulcer disease 5.6 5.4 0.826 
    Liver disease 7.0 6.5 0.690 
    Diabetes 35.4 37.1 0.467 
    Renal disease 29.8 30.0 0.913 
    Solid tumor 10.4 10.1 0.869 
    Metastases 27.6 27.9 0.911 
    HIV/AIDS 1.8 1.5 0.693 
    GERD 31.3 31.0 0.914 
    Transplant 2.8 2.9 0.880 
    Inflammatory bowel disease 1.5 1.9 0.560 
    Irritable bowel syndrome 0.4 0.4 1.000 
Charlson score, median (IQR) 6 (4-9) 6 (4-9) 0.844 
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Concomitant infections, %    
    Bacteremia 4.9 5.1 0.819 
    Pneumonia 21.2 20.5 0.712 
    Skin infection 6.1 5.5 0.593 
    Intra-abdominal infection 3.3 3.3 1.000 
    Device-related infection 1.5 2.1 0.349 
    Acute respiratory infection 1.0 1.0 1.000 
    Endocarditis 0.6 0.4 0.478 
    Urinary tract infection 2.5 2.1 0.618 
CDI severity indicators, %    
    ICU admission 2.0 2.0 1.000 
    Sepsis/septicemia 19.9 19.1 0.705 
    Shock 5.1 4.0 0.281 
    Acute renal failure 32.1 31.0 0.628 
    Megacolon 0.1 0.0 0.317 
    Prolonged ileus 4.1 4.0 0.899 
    Perforated intestine 0.3 0.9 0.095 
    WBC ≥15,000 cells/µL 42.8 45.3 0.314 
    CRP ≥160 mg/L 1.6 1.3 0.529 
    Albumin <2.5 g/dL 44.9 43.4 0.546 
Medications, %    
    Prior antibiotics 63.3 61.1 0.381 
    Prior GAS drugs 62.9 61.0 0.440 
    Prior narcotics 48.8 47.5 0.617 
    Prior anti-diarrheals 8.3 9.4 0.427 
    Prior bowel prep 23.1 22.0 0.590 
    Concomitant antibiotics 75.0 74.4 0.774 
    Concomitant GAS drugs 80.1 79.4 0.709 
    Concomitant narcotics 59.8 57.1 0.287 
    Concomitant anti-diarrheals 10.5 10.0 0.742 
    Concomitant bowel prep 23.6 23.9 0.907 
CDI therapies, %    
    Rifaximin 0.8 1.0 0.591 




Figure 5.3 Comparative-effectiveness of metronidazole and vancomycin on CDI health 
















DISCUSSION AND CONCLUSIONS 
 
Specific Aim 1 
In this aim, we explored the impact of cancer diagnosis on CDI risk. We found 
that cancer was associated with a 1.4 fold increased risk for CDI compared to no cancer 
diagnosis. Importantly, we also found that certain cancer diagnoses more strongly 
increased CDI risk. Specifically, patients with metastases or lymphatic/hematologic 
cancers were at highest risk compared to other cancer types.  
Our findings that cancer increases risk for CDI are in-line with prior studies. 
While few other studies have assessed cancer as an independent risk factor for CDI, 
multiple studies have documented significantly higher rates of CDI among cancer 
patients. In our prior work analyzing U.S. community hospitals, the incidence of CDI 
among cancer patients was 1.4 times higher than non-cancer patients.37  
The mechanism by which cancer increases the risk for CDI is likely multifaceted. 
First, cancer patients are often exposed to the health care system to a greater degree, 
which increases their likelihood of acquired C. difficile spores from the environment. 
Prior studies have found that hospitalized patients (4-29%) have significantly higher C. 
difficile colonization rates compared to health adults (0-15%).1 They are also more likely 
to develop clinical infection after spore acquisition due to several reasons. Cancer 
patients are often exposed to medications that disrupt the normal gut microbiota, such as 
antibiotics and chemotherapeutic agents. Dysbiosis then reduces the host’s ability to 
protect against pathogens, like C. difficile. Furthermore, cancer is associated with 
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immunosuppression; thus, cancer patients may not be able to mount an adequate immune 
response to C. difficile toxins once spores begin to germinate. 
It’s important to note that cancer was not the primary risk factor for CDI.  
Transplant was the strongest predictor of CDI, followed by paraplegia/hemiplegia, 
inflammatory bowel disease, liver disease, HIV/AIDS, and prior antibiotic use. Some of 
these are well-known risk factors, while others have not been previously reported.  
HSCT patients are traditionally one of the highest risk groups for CDI,39 likely 
due to immunosuppression and health care exposures. Prior antibiotic use is another 
classic risk factor for CDI due to its gut microbiome-mediating effects,14 which reduce 
the host’s ability for colonization resistance. Lastly, patients with inflammatory bowel 
disease have been previously reported to be at higher risk for CDI. This is likely due to 
colonic inflammation and significant differences in host gut microbiome in IBD patients 
compared to non-IBD patients.78  
One of the more interesting risk factors identified in this study was 
paraplegia/hemiplegia. To our knowledge, this has not been reported in prior studies. 
This could be, in part, due to the generally low prevalence of this diagnosis in the general 
population, but higher prevalence among veterans. We hypothesize that the risk for these 
patients may be related to healthcare exposures (hospitalizations, enteral feedings) or 
limited mobility, which may impact overall gut health.  
Next, in this study we found that certain cancer patients were at higher risk for 
CDI compared to others. Patients with metastases were especially at higher risk. This is 
likely due to greater degree of healthcare exposures and immunosuppression due to 
disease and drug therapy. To our knowledge, this is the first study to identify this specific 
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relationship; therefore, further studies are needed to elucidate the mechanisms for this 
relationship.  
Hematologic malignancies were also associated with increased CDI risk. This is 
consistent with our prior work that demonstrated that the incidence of CDI among 
hematologic cancers was more than double that of solid cancer types.37 A retrospective 
review of leukemia patients revealed that CDI occurred in 7% of all cycles of 
myelosuppressive chemotherapy.59 Lastly, an analysis of 134 patients found that CDI 
occurred in 18% of patients with acute myeloid leukemia and in 9% of all treatment 
courses.79 The relationship is likely due to healthcare exposures as described in the 
background. Patients with blood cancers might receive antibiotics at a higher rate due to a 
higher incidence of neutropenic fever resulting from cytotoxic chemotherapy and direct 
effects on host immunity.50 Furthermore, patients with blood cancers tend to have a 
longer length of stay during hospitalizations compared to solid tumor patients.80 Lastly, 
hematologic malignancies have the therapeutic option of HSCT. When comparing HSCT 
recipients versus other cancer patients, Chopra et al.39 reported HSCT recipients to have 
1.4 times higher CDI rates. It is hypothesized these differences are due to chemotherapy 
regimens and antibiotic use leading up to transplantation, in addition to prolonged 
hospital stay.47,52,53 The distinction between hematologic malignancy versus solid tumor is 
of importance in CDI prevention and treatment. Due to the increased risk associated with 
hematologic malignancies, more diligent antimicrobial stewardship may be warranted 
along with potentially more aggressive CDI treatment. To our knowledge, this is the first 




Specific Aim 2 
In this aim, we compared CDI clinical outcomes between cancer and non-cancer 
patients. We found that a cancer diagnosis was associated with a 1.4 fold increase in risk 
for 30-day mortality compared to no cancer diagnosis. Cancer was not associated with 
risk differences in 60-day recurrence or hospital LOS though. Important, hematologic 
cancers resulted in significantly higher risk for mortality compared to solid cancers.  
This was one of the first studies to evaluate the impact of cancer on CDI health 
outcomes. In our prior study of the U.S. National Hospital Discharge Surveys, cancer 
patients with CDI had significantly higher mortality (9.4% vs. 7.5%, p<0.0001) and 
longer median LOS (9 days vs. 4 days, p<0.0001). 
We hypothesize that the increased risk for mortality seen among cancer patients is 
likely related to the overall underlying health status. Cancer is associated with higher 
mortality compared to the general population and CDI may simply exacerbate this 
association. Furthermore, in this dataset, cancer patients were older and had higher rates 
of other comorbidities. We were not able to verify cause of death; therefore, death could 
have been specifically related to the cancer, CDI, or something entirely else.  
Importantly, cancer diagnosis was not associated with a longer hospital length of 
stay or increased risk for CDI recurrence. This is in contrast to our prior work, which 
found that median LOS for cancer patients with CDI was significantly longer than non-
cancer patients (9 vs. 4 days; p<0.0001). These prior data were taken from U.S. 
community hospitals, exclusive of veterans. The older, generally sicker veteran 
population may help explain these differences. The higher rates of mortality among 
cancer patients may help explain the lack of association between cancer and CDI 
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recurrence – cancer patients may die before they have the chance to develop recurrence 
(i.e., survival bias).  
Hematologic malignancies were especially related to increased risk for mortality. 
We believe that this is also related to underlying health status and general progression of 
cancer as described previously. Similar to cancer status overall, hematologic 
malignancies were not associated with longer LOS or higher risk for recurrence 





Specific Aim 3 
Aim 3 of this dissertation was a comparative-effectiveness study comparing oral 
metronidazole to oral vancomycin on CDI health outcomes among cancer patients. 
Interestingly, we found no significance difference between groups in risk for 30-day 
mortality; however, risk for 60-day CDI recurrence and hospital LOS ≥14 days were 
significantly increased among patients treated with vancomycin.  
To our knowledge, no other studies have compared clinical outcomes between 
metronidazole and oral vancomycin-treated patients, specifically in the cancer 
population. Metronidazole therapy, in general, has fallen out of favor due to a single 
clinical trial in non-cancer patients that demonstrated significantly higher rates of clinical 
cure with oral vancomycin.72 A more recent randomized controlled trial found higher 
clinical cure among CDI cancer patients treated with fidaxomicin compared to 
vancomycin.73 While our results are somewhat different than these prior studies, a recent 
study in the VHA found that metronidazole was not associated with increased mortality 
risk compared to vancomycin in younger (<65 years old) VA patients with mild CDI.81 
Our findings suggest that metronidazole may still be appropriate for veterans with CDI. 
Although mortality was not significantly different between groups, vancomycin 
use was associated with significantly higher rates of CDI recurrence and longer hospital 
LOS. While we cannot determine the reason for this association in the current analysis, 
we suspect this is due to access issues in the outpatient setting. While metronidazole is 
available as an oral capsule and is dosed twice daily, oral vancomycin capsules are 
significantly more expensive and are dosed four times per day. Many patients were 
expected to locate a compounding pharmacy to access oral vancomycin compounded 
from the intravenous solution. This could considerably impact patient compliance, though 
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studies validating this association are lacking. In 2018, an oral vancomycin suspension 
was approved, which is less expensive than the capsules. This may aid in improved 






This study has several strengths. First, we collected data on all patients with CDI 
managed at any VHA facility over a 12-year period. The VHA is the largest integrated 
health care system in the U.S. and is national in scope. This provided for a large sample 
size, which enabled more robust statistical analyses. These data supplement existing 
national database CDI studies that do not include information on federal facilities (e.g., 
CDC’s National Hospital Discharge Surveys, AHRQ’s Healthcare Cost and Utilization 
Project, AHRQ’s Medical Expenditure Panel Surveys).  
The VHA maintains a comprehensive computerized system that contains patient 
and provider demographics, inpatient and outpatient data, laboratory data, and pharmacy 
data. This enabled the study of many relevant variables and patient outcomes. We studied 
objective variables that are readily obtained in the normal course of a patient’s clinical 
evaluation. We included variables that have been previously identified as risk factors for 
CDI and its outcomes. We also identified previously unknown CDI risk factors.  
The VHA enabled us to collect data on outpatient CDI. Outpatients have rarely 
been studied previously due to lack of reporting and follow-up in the outpatient setting. 
The VHA system allowed us to capture outpatient information, thus filling a significant 
knowledge gap regarding the epidemiology of community-onset CDI.  
CDI disproportionately affects older patients and those with underlying 
conditions; the VHA population is a major asset in that regard. Although men and elderly 
patients are over-represented in this population, as compared to community hospitals, this 
population is racially, ethnically, and medically diverse. Acute and chronic illness are 
common among VHA patients, thus our population is likely representative of CDI 




This study has potential limitations. First, we utilized a retrospective study design 
that includes data collection from electronic medical records. This design has inherent 
limitations. Case-control and cohort studies might be subject to misclassification bias and 
confounding by unmeasured variables. Multivariable logistic regression techniques and 
internal validation were used in an attempt to account for confounders and limit any 
potential biases; however, these methods cannot fully account for all confounders and are 
not equivalent to a prospective, randomized study.  
Specifically, we were unable to control for specific chemotherapy regimens in our 
analysis. Chemotherapy varies by regimen, different regimens for different cancer types. 
Different cancer severity may lead to different treatment intensity.  
Cancer diagnoses don’t account for late vs. early stage. A solid tumor could be a 
metastasis. Other cancer severity factors weren’t included. Tried to use metastasis as a 
control for severity? Future study could focus on one cancer type, or compare those 
where the problem seemed really apparent.  
The data were also collected from 2002 to 2014, which may not reflect current 
CDI epidemiology or treatment practices, especially with the release of the new CDI 
clinical practice guidelines in 2018. Drug selection preferences change over time. 
Perceived difference in treatment need due to severity of illness or overall health state 
may lead to “sicker” patients being treated with specific drug over another. General lag of 
real change after guideline publication. Cost also contributes largely. Future study could 
stratify by year. 
The use of electronic medical records for data collection is also subject to 
limitations. Electronic medical data are created for the purpose of patient care, not for 
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research, and might contain errors. There might be variation in the extent of physician 
reporting of certain medical conditions; variability might lead to inaccuracy of the 
Charlson comorbidity score and other variables. Importantly, we relied on ICD-9-CM 
codes and CCS codes to identify CDI and other comorbidities. Although prior studies 
have demonstrated good sensitivity and specificity of CDI ICD-9-CM codes (71 to 78% 
and >99%, respectively) compared to microbiologic data,82 administrative data might not 
fully capture every patient with CDI. Similarly, other comorbidities might not be fully 
captured using administrative codes and cannot be considered equivalent to medical chart 
reviews. Furthermore, fidaxomicin and other CDI therapies (FMT, rifaximin, 
nitazoxanide) use were low in this population; thus, we were not able to compare its 
effects on CDI clinical outcomes.  
Finally, this study contained a predominately male VHA population; therefore, 




Conclusions & Future Directions 
CDI is an important public health problem in the Veterans Health Care System. In 
this nationally representative study of veterans, we found that cancer was an independent 
risk factor for CDI. Certain types of cancers were more strongly associated with CDI, 
including metastatic cancer and lymphatic/hematologic cancers. Next, cancer was an 
important risk factor for poor CDI health outcomes. Patients with cancer who develop 
CDI and more likely to experience 30-day all-cause mortality compared to those without 
cancer; however, cancer does not appear to strongly influence CDI recurrence or hospital 
LOS. Finally, CDI cancer patients treated with metronidazole or vancomycin had similar 
risk for 30-day mortality, but vancomycin was associated with a higher risk for 
recurrence and longer hospital stay.  
CDI treatment and preventative initiatives should remain a national priority in the 
U.S. Newer therapies and clinical strategies are needed to reduce the risk of CDI and 
recurrences and improve the health outcomes of patients with CDI. Given that cancer 
patients are at higher risk for CDI compared to non-cancer patients, this group should be 
specifically targeted for preventative initiatives. Further studies are also needed to 






AIDS Acquired immunodeficiency syndrome 
CA-CDI Community-associated C. difficile infection 
CDI Clostridioides difficile infection 
CHF Congestive heart failure 
CI Confidence interval 
CO-HCFA-CDI Community-onset, healthcare facility-associated CDI 
COPD Chronic obstructive pulmonary disease 
CO-HCFA-CDI Community-onset, healthcare facility-associated CDI 
CRP C-reactive protein 
FDX Fidaxomicin 
FMT Fecal microbiota transplantation 
GAS Gastric acid suppressant 
GERD Gastroesophageal reflux disease 
HCFO-CDI Healthcare facility-onset CDI 
HIV Human immunodeficiency virus 
H2RA Histamine-2 receptor agonist 
HSCT Hematopoietic stem cell transplant 
IBD Inflammatory bowel disease 
IBS Irritable bowel syndrome 
IDSA Infectious Diseases Association of America 
ICD-9-CM International Classification of Diseases, 9th Revision, Clinical 
Modification 
ICU Intensive care unit 
IV Intravenous 
LOS Length of stay 
OR Odds ratio 
PO Per oral (route of administration) 
PPI Proton pump inhibitor 
PR Per rectum (route of administration) 
SCFA Short-chain fatty acid 
SCr Serum creatinine 
SHEA Society for Healthcare Epidemiology in America 
US United States 
VHA Veterans Health Administration 
VINCI Veterans Affairs Informatics and Computing Infrastructure 
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